Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply

Persson, Monica S.M. and Sarmanova, Aliya and Doherty, Michael and Zhang, Weiya (2018) Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply. Rheumatology . ISSN 1462-0332 (In Press)

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (60kB) | Preview

Abstract

MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ reports honoraria for Grunenthal and speaker fees for Bioiberica and Hisun, outside the submitted work. All other authors have declared no conflicts of interest.

Item Type: Article
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Rheumatology, Orthopaedics and Dermatology
Depositing User: Lashkova, Mrs Olga
Date Deposited: 05 Sep 2018 08:09
Last Modified: 08 Aug 2019 04:30
URI: http://eprints.nottingham.ac.uk/id/eprint/53706

Actions (Archive Staff Only)

Edit View Edit View